ResMed Income Statement
Revenue, expenses, and profitability over time
ResMed generated $5.7B in trailing twelve-month revenue, up 0.1% year-over-year. Net income was $1.5B with a 26.8% net margin. Gross margin stands at 62.29% and operating margin at 34.47%. Diluted EPS is $10.36, which grew 0.1% year-over-year. Based on the Q1 2026 filing.
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$27.9B
P/E Ratio18.41
ROE25.19%